MNMina Nikanjam

Mina Nikanjam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mina Nikanjam has a total of 91 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Table 1 from GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to Immunotherapy

    by Peter Moussa, Razelle Kurzrock, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mina Nikanjam, Taylor J. Jensen, Jeffrey M. Conroy, Paul DePietro, Jason K. Sicklick, et al.

    Supplementary table 1 shows baseline characteristics (sex and age) as well as breakdown of malignancy types in patients included in analysis

  • Open Access

    Supplementary Table 2 from GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to Immunotherapy

    by Peter Moussa, Razelle Kurzrock, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mina Nikanjam, Taylor J. Jensen, Jeffrey M. Conroy, Paul DePietro, Jason K. Sicklick, et al.

    Supplementary table 2 exploring the relationship of median overall survival with high GITR and high GITR plus low/moderate GITR-L RNA expression in patients who received immunotherapy via COX analysis failed to reveal a relationship between survival and high GITR as well as high GITR plus low/moderate GITR-L expression on univariate analysis, but multivariate analysis implied better median overall survival in patients with high GITR plus low/moderate GITR-L expression when accounting for the RNA expression of other immunomodulatory proteins on multivariate analysis

  • Open Access

    Figure from GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to Immunotherapy

    by Peter Moussa, Razelle Kurzrock, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mina Nikanjam, Taylor J. Jensen, Jeffrey M. Conroy, Paul DePietro, Jason K. Sicklick, et al.

    Supplementary figure 1 showing no PFS benefit in patients who received IO regardless of GITR and GITR-L levels

  • Open Access

    Data from GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to Immunotherapy

    by Peter Moussa, Razelle Kurzrock, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mina Nikanjam, Taylor J. Jensen, Jeffrey M. Conroy, Paul DePietro, Jason K. Sicklick, et al.

    Glucocorticoid-induced tumor necrosis factor–related protein (GITR) is an immune stimulator; however, the correlation between GITR and GITR ligand (GITR-L) expression levels and patient outcomes is not yet characterized. This study explores transcript expression patterns of GITR and GITR-L in relation to outcomes in 489 patients with advanced/metastatic cancers. Given that survival curves for the different subgroups analyzed did not show proportional hazards, restricted mean survival time (RMST) analysis was utilized. In multivariate analysis accounting for RNA expression of other immune modulators, high GITR expression correlated with better RMST in all 489 patients and in the subset of 272 patients who did not receive immunotherapy (all P < 0.05), but not in the 217 patients who received immunotherapy. On the other hand, high GITR plus low/moderate GITR-L expression correlated with longer overall survival in patients who received immunotherapy (multivariate P < 0.05), but not in the patients who did not receive immunotherapy. No GITR-correlated progression-free survival associations were observed in patients who received immunotherapy. Finally, the immunomodulator proteins inducible T-cell costimulator and CD226 were associated with a significantly improved mean survival in patients with a high GITR plus low/moderate RNA expression pattern who received immunotherapy. Overall, these results suggest that high GITR RNA expression may be independently prognostic of better RMST in patients with advanced/metastatic cancers, but only the combination of high GITR plus low/moderate GITR-L expression is independently predictive of better RMST after treatment with immunotherapy.

  • Open Access

    Supplementary Figure 1 Legend from GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to Immunotherapy

    by Peter Moussa, Razelle Kurzrock, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mina Nikanjam, Taylor J. Jensen, Jeffrey M. Conroy, Paul DePietro, Jason K. Sicklick, et al.

    Supplementary figure 1 showed no preferential PFS benefit in patients who were either high GITR or high GITR plus GITR-L low/moderate who received immunotherapy

  • Claudin 18.2 Targeting: A Pan-Cancer Perspective

    by Mina Nikanjam, Judith Pérez-Granado, Mark W. Gramling, Bruno Larvol, Razelle Kurzrock

    Claudin 18.2 (CLDN18.2) is exclusively expressed on gastric mucosal cell tight junctions with minimal expression in other healthy adult tissues. Prior studies assessed expression by immunohistochemistry, mainly membrane staining. The FDA CLDN18.2 threshold for zolbetuximab approval is ≥75% moderate to strong staining. Higher level expression has been seen in a number of cancers including (but not limited to) gastric, gastroesophageal junction (GEJ), pancreatic, and ovarian cancers. CLDN18.2 expression can change with treatment and can exhibit heterogeneity between tumor sites. Zolbetuximab is a recently FDA-approved anti-CLDN18.2 monoclonal antibody for first-line therapy of gastric/GEJ cancers in combination with chemotherapy based on the improvement in outcomes demonstrated in the biomarker selected populations of the SPOTLIGHT and GLOW trials. Given limited single-agent responses rates to zolbetuximab, a number of other CLDN18.2-directed therapies, including antibody-drug conjugates, CAR-T cells, and bispecific antibodies, are under exploration in clinical trials. Despite expression of CLDN18.2 on the gastric mucosa, these therapies have overall been tolerable in clinical trials, albeit with the use of aggressive anti-emetic regimens. Herein, we summarize CLDN18.2 expression in cancer along with clinical trials of zolbetuximab and other CLDN18.2-directed therapies. Given the variability in CLDN18.2 expression within and between tumor types, biomarker-driven approaches will be critical for patient selection in clinical trials and therapeutic approaches.


  • GITR and GITR-L RNA Expression Levels Correlate with Better Survival and Response to Immunotherapy

    by Peter Moussa, Razelle Kurzrock, Daisuke Nishizaki, Hirotaka Miyashita, Suzanna Lee, Mina Nikanjam, Taylor J. Jensen, Jeffrey M. Conroy, Paul DePietro, Jason K. Sicklick, et al.

    Glucocorticoid-induced tumor necrosis factor–related protein (GITR) is an immune stimulator; however, the correlation between GITR and GITR ligand (GITR-L) expression levels and patient outcomes is not yet characterized. This study explores transcript expression patterns of GITR and GITR-L in relation to outcomes in 489 patients with advanced/metastatic cancers. Given that survival curves for the different subgroups analyzed did not show proportional hazards, restricted mean survival time (RMST) analysis was utilized. In multivariate analysis accounting for RNA expression of other immune modulators, high GITR expression correlated with better RMST in all 489 patients and in the subset of 272 patients who did not receive immunotherapy (all P < 0.05), but not in the 217 patients who received immunotherapy. On the other hand, high GITR plus low/moderate GITR-L expression correlated with longer overall survival in patients who received immunotherapy (multivariate P < 0.05), but not in the patients who did not receive immunotherapy. No GITR-correlated progression-free survival associations were observed in patients who received immunotherapy. Finally, the immunomodulator proteins inducible T-cell costimulator and CD226 were associated with a significantly improved mean survival in patients with a high GITR plus low/moderate RNA expression pattern who received immunotherapy. Overall, these results suggest that high GITR RNA expression may be independently prognostic of better RMST in patients with advanced/metastatic cancers, but only the combination of high GITR plus low/moderate GITR-L expression is independently predictive of better RMST after treatment with immunotherapy.

  • Top Cited Papers
    Open Access

    Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT) N-of-1 Precision Oncology Study: Molecular Profiling to Match Individually Dosed, Personalized Drug Combinations

    by Jason K. Sicklick, Daisuke Nishizaki, Hirotaka Miyashita, Ryosuke Okamura, Michael E. Hahn, Mina Nikanjam, Paul T. Fanta, David E. Piccioni, Hitendra Patel, Ramez N. Eskander, et al.

    PURPOSE: Malignancies have complex and distinct molecular profiles that may not segregate by tumor type. However, most precision oncology treatments are matched to a single biomarker. We aimed to optimize therapy for advanced cancers using individually dosed drug regimens customized to cotarget multiple molecular alterations. METHODS: Investigation of Profile-Related Evidence Determining Individualized Cancer Therapy (I-PREDICT; NCT02534675 ) is a prospective, investigator-initiated, multidepartment/pan-cancer trial for aggressive advanced/metastatic malignancies. Patients had tissue and/or blood next-generation sequencing (NGS; Foundation Medicine). A molecular tumor board made suggestions. Degree of biomarker matching to drugs given was calculated by a matching score (MS; broadly, number of pathogenic alterations targeted divided by total pathogenic alterations). RESULTS: Overall, 210 evaluable patients (n = 456 consented) received ≥1 US Food and Drug Administration–approved drug (mostly off label) after NGS. Median number of pathogenic alterations/tumor was five (range, 0-20); approximately 95% of patients had unique molecular landscapes. Consistent with I-PREDICT's objective to optimize/tailor treatment for each patient, we administered 157 different regimens (including 103 personalized combinations without established safety/dosing data). For previously unstudied combinations, starting doses were reduced and titrated to tolerance (intrapatient dose-finding); only 6.5% experienced Grade 3/4 drug-related toxicities ( v 15.5% of those receiving established regimens). Higher disease control rate (stable disease ≥6 months/objective response), and longer progression-free survival and overall survival correlated significantly/independently/linearly with greater degrees of drug matching to alterations (higher MS), but did not vary by drug number or dosages. CONCLUSION: The I-PREDICT strategy of maximizing personalized biomarker matching with individually dosed customized drug combinations enabled safe and active N-of-1 matched treatment, including regimens previously unstudied in Phase I trials. I-PREDICT represents a blueprint for a new personalized precision oncology paradigm, which merits validation via additional prospective trials.


  • Open Access

    Inducible T‐Cell Co‐Stimulator ( ICOS ) and ICOS Ligand: Dealing With a Two‐Faced Cancer Immunoregulatory System

    by Mina Nikanjam, Shumei Kato, Daisuke Nishizaki, Hirotaka Miyashita, Sarabjot Pabla, Mary K. Nesline, Heidi Ko, Jeffrey M. Conroy, Aung Naing, Razelle Kurzrock

    Background: ICOS (inducible T‐cell co‐stimulator) and ICOS ligand (ICOSL) are part of an important, complex pathway that can lead to both immune stimulation and suppression. ICOS and ICOSL have heterogeneous expression patterns between and within tumor types. Methods: This review provides an overview of ICOS and ICOSL, their mechanisms of action, expression in cancer and other diseases, and clinical trials exploring therapies targeting ICOS. Results: Because of the bidirectional immune impact of the ICOS/ICOSL signaling pathway, both ICOS agonists and antagonists are under development and evaluation in clinical trials. The majority of clinical trials have focused on the development of ICOS agonists, with only one study exploring an ICOS antagonist; there have been no clinical trials developing ICOSL agonists or antagonists in oncology. ICOS can be expressed on immune‐activating effector T‐cell and immunosuppressive regulatory T‐cell (Tregs). Thus, it is critical to determine where and how ICOS is expressed in order to evaluate the role for agonists versus antagonists. To date, ICOS agonists have shown limited activity in patients with malignancies, perhaps because of the lack of biomarker‐based trials. However, an ICOS antagonist demonstrated a 44% response rate in angioimmunoblastic T‐cell lymphoma; ICOS is highly expressed on T‐follicular helper cells (type of CD4 cell) and proliferation of these cells may be a pathogenic mechanism for these lymphomas. A role for the ICOS/ICOSL signaling pathway has also been implicated outside of oncology, including in viral infections such as COVID‐19, and in autoimmune conditions such as asthma and systemic lupus erythematosus. Conclusion: Biomarker‐driven approaches will be important to individualize therapy and ascertain which cancer patients will derive the greatest benefit from ICOS‐directed combination therapy approaches.